Technology Insight: Therapeutic RNA interference - How far from the neurology clinic?

Nature Clinical Practice Neurology

Volumn 3, Issue 7, 2007, Pages 394-404

  Gonzalez Alegre, Pedro ^a   Paulson, Henry L ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; ATAXIN 1; COPPER ZINC SUPEROXIDE DISMUTASE; HERPESVIRUS VECTOR; HUNTINGTIN; LENTIVIRUS VECTOR; LIPOSOME; MICRORNA; PARVOVIRUS VECTOR; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; FAMILIAL DISEASE; GENE SILENCING; HUMAN; HUNTINGTON CHOREA; IMMUNOSTIMULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SPINOCEREBELLAR DEGENERATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; GENE THERAPY; HUMANS; NEURODEGENERATIVE DISEASES; RNA INTERFERENCE;

EID: 34447268648     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0551     Document Type: Review

References (78)

1. Fire A et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811
2. Paulson H and Gonzalez-Alegre P (2006) RNAi gets its prize. Lancet Neurol 5: 997-999
3. Gonzalez-Alegre P (2007) Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacol Ther 114: 34-55
4. Davidson BL and Paulson HL (2004) Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol 3: 145-149
5. Rodriguez-Labron E and Gonzalez-Alegre P (2006) Silencing neurodegenerative disease: Bringing RNA interference to the clinic. Expert Rev Neurother 6: 223-233
6. Bartel DP (2004) MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297
7. Carmell MA and Hannon GJ (2004) RNase III enzymes and the initiation of gene silencing. Nat Struct Mol Biol 11: 214-218
8. Cullen BR (2004) Transcription and processing of human microRNA precursors. Mol Cell 16: 861-865
9. Du T and Zamore PD (2005) microPrimer: The biogenesis and function of microRNA. Development 132: 4645-4652
10. Kim VN (2005) MicroRNA biogenesis: Coordinated cropping and dicing. Nat Rev Mol Cell Biol 6: 376-385
11. Meister G and Tuschi T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343-349
12. Murchison EP and Hannon GJ (2004) miRNAs on the move: MiRNA biogenesis and the RNAi machinery. Curr Opin Cell Biol 16: 223-229
13. Tomari Y and Zamora PD (2005) Perspective: Machines for RNAi. Genes Dev 19: 517-529
14. Tomari Y and Zamore PD (2005) MicroRNA biogenesis: Drosha can't cut it without a partner. Curr Biol 15: R61-R64
15. Meister G et al. (2004) Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 15: 185-197
16. Miller VM et al. (2005) RNA interference in neuroscience: Progress and challenges. Cell Mol Neurobiol 25: 1195-1207
17. Gunsalus KC and Piano F (2005) RNAi as a tool to study cell biology: building the genome-phenome bridge. Curr Opin Cell Biol 17: 3-8
18. Dykxhoom DM and Lieberman J (2005) The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med 56: 401-423
19. Bentwich I et al. (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37: 766-770
20. Berezikov E et al. (2005) Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120:21-24
21. Xie X et al. (2005) Systematic discovery of regulatory motifs in human promoters and 3[prime] UTRs by comparison of several mammals. Nature 434: 338-345
22. Lim LP et al. (2005) Microarray analysis shows that some microRNAs downregulate Large numbers of target mRNAs. Nature 433: 769-773
23. Jackson RJ and Standart N (2007) How do microRNAs regulate gene expression? Sci STKE 2007: Re1
24. Liu J et al. (2005) MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 7: 719-723
25. Kosik KS (2006) The neuronal microRNA system. Nat Rev Neurosci 7: 911-920
26. Giraldez AJ et al. (2005) MicroRNAs regulate brain morphogenesis in zebrafish. Science 308: 833-838
27. Jin P et al. (2004) RNA and microRNAs in fragile X mental retardation. Nat Cell Biol 6: 1048-1053
28. Bumcrot D et al. (2006) RNAI therapeutics: A potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719
29. Shankar P et al. (2005) The prospect of silencing disease using RNA interference. JAMA 293: 1367-1373
30. Kim DH and Rossi JJ (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184
31. Izqierdo M (2005) Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 12: 217-227
32. Ketzinel-Gilad M et al. (2006) RNA interference for antiviral therapy. J Gene Med 8: 933-950
33. Paulson HL (2000) Toward an understanding of polyglutamine neurodegeneration. Brain Pathol 10: 293-299
34. Paulson HL et al. (2000) Polyglutamine disease and neuronal cell death. Proc Natl Acad Sci USA 97: 12957-12958
35. Gonzalez-Alegre P and Paulson HL (2004) Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. J Neurosci 24: 2593-2601
36. Goodchild RE and Dauer WT (2004) Mislocalization to the nuclear envelope: An effect of the dystonia-causing torsinA mutation. Proc Natl Acad Sci USA 101: 847-852
37. Rodriguez-Lebron E and Paulson HL (2006) Allele-specific RNA interference for neurological disease. Gene Ther 13: 576-581
38. Gonzallez-Alegre P et al. (2003) Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Ann Neurol 53: 781-787
39. Gonzalez-Alegre P et al. (2005) Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci 25: 10502-10509
40. Miller VM et al. (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 100: 7195-7200
41. Schwarz DS et al. (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2: E140
42. Marcotte L and Crino PB (2006) The neurobiology of the tuberous sclerosis complex. Neuromolecular Med 8: 531-546
43. Singleton AB et al. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302: 841
44. Paulson H and Ammache Z (2001) Ataxia and hereditary disorders. Neurol Clin 19: 759-782, viii
45. Humbert S and Saudou F (2002) Toward cell specificity in SCA1. Neuron 34: 669-670
46. Matilla A et al. (1998) Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. J Neurosci 18: 5508-5516
47. Zu T et al. (2004) Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci 24: 8853-8861
48. Xia H et al. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10: 816-820
49. Ralph GS et al. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11: 429-433
50. Raoul C et al. (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 11: 423-428
51. Saito Y et al. (2005) Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model. J Biol Chem 280 42826-42830
52. Xia X et al. (2006) Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis 23: 578-586
53. Sapru MK et al. (2006) Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 198: 382-390
54. Harper SQ et al. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102: 5820-5825
55. Rodriguez-Lebron E et al. (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 12: 618-633
56. Machida Y et al. (2006) rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun 343: 190-197
57. Wang YL et al. (2005) Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci Res 53: 241-249
58. Singer O et al. (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8: 1343-1349
59. Hong CS et al. (2006) Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's dissease-related amyloid-β peptide in vivo. Gene Ther 13: 1068-1079
60. Pfeifer A et al. (2006) Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 116: 3204-3210
61. Davidson BL and Breakefield XO (2003) Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 4: 353-364
62. Fountaine TM et al. (2006) Delivering RNA interference to the mammalian brain. Curr Gene Ther 5: 399-410
63. Sah DW (2006) Therapeutic potential of RNA interference for neurological disorders. Life Sci 79: 1773-1780
64. Grimm D et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541
65. Alvarez VA et al. (2006) Retraction of synapses and dendritic spines induced by off-target effects of RNA interference. J Neurosci 26: 7820-7825
66. Stark GR et al. (1998) How cells respond to interferons. Annu Rev Biochem 67: 227-264
67. Bridge AJ et al. (2003) Induction of an interferon response by RNAi vectors in mammalian calls. Nat Genet 34: 263-264
68. Jackson AL et al. (2006) Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12: 1179-1187
69. Judge AD et al. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462
70. Pebemard S and Iggo RD (2004) Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 72: 103-111
71. Sledz CA et al. (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834-839
72. Heidel JD et al. (2004) Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22: 1579-1582
73. Birmingham A et al. (2006) 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3 199-204
74. Qiu S et al. (2005) A computational study of off-target effects of RNA interference. Nucleic Acids Res 33: 1834-1847
75. Khvorova A et al. (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216
76. Schwarz DS et al. (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208
77. Zang Y et al. (2003) MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 100: 9779-9784
78. Miller N and Whelan J (1997) Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther 8: 803-815